News

Sense raises € 4.5 million to improve measurement of blood pressure

2012-02-13


The Danish company Sense A/S just raised € 4.5 million for their groundbreaking medical technology for blood pressure measurement. The technology works seamlessly and will remedy incorrect diagnostics of hypertension at the physicians' offices, which themselves can cause elevated readings. The total investment from venture fund SEED Capital and Vækstfonden will be used to refine the product and for commercial launch in 2013.

High blood pressure affects more than ¼ of the Western world population and it is estimated that up to 12% of all deaths can be linked to this disorder. Hypertension is therefore one of the world's largest disease areas and the most important factor in the treatment of this is an accurate diagnosis. Current diagnostic solution of choice is the measurement of blood pressure at the physicians' offices, and typically using the cuff method. However this solution has a number of challenges including discomfort with the measurement itself and nervousness during the consultation which both may contribute to erroneous measurements. In addition, the realization is that a variety of cardiovascular diseases can be diagnosed much better by measuring blood pressure over a standard 24-hour circadian rhythm, and for this the cuff method is not very suitable.

The Danish company Sense A/S develops ContiPress™, which continuously measures the patient's blood pressure 24 hours a day, down to every 10 second day and night, without the user noticing. ContiPress™ consists of an intelligent patch, which the doctor or nurse places on the patient's upper arm. From there, the unit monitors the patient's blood pressure over 24 hours and stores the data for subsequent analysis via an enclosed piece of software. The result is comprehensive data about the patient's blood pressure over 24 hours and thus an optimal basis for making the correct diagnosis.

Sense has raised € 4.5 million in an investment round with venture fund SEED Capital and Vækstfonden. It is the company third round, since it was founded in 2006 in connection with an investment from SEED Capital. Second round of investment came from SEED Capital and Vækstfonden in 2010. ContiPress™ is currently a prototype that has been clinically tested on people with very large differences in both blood pressure, BMI (body mass index) and age with promising results that verify the measurement principle. The investment round will be used to refine the device and try ContiPress™ in a more extensive clinical testing within the expected commercial launch.

Contact: 
More info: 

News archive

  • 2015-04-15

    SEED Capital welcomes crowdsourced weather service in portfolio

    We are pleased to announce Vaavud as our newest investment and are looking forward to pursuing the goal of supplying high-resolution, personalized weather forecasts.

  • 2015-03-30

    Windar Photonics admitted to trading on AIM

    Windar Photonics admitted to trading on AIM Today it is announced that Windar Photonics has been listed on AIM London Stock Exchange in pursuit of growth. The valuation of the company is approximately 54 million dollars.

  • 2015-03-27

    Redegørelse

    Redegørelse om påtale til SEED Capital Management I/S for at undlade at registrere sig som forvalter af alternative investeringsfonde.

  • 2015-03-25

    The Managing Director of Momondo, Pia Vemmelund takes the helm at Bownty

    Every year Bownty sell deals worth hundreds of millions, while revenue has tripled the past year alone. Internalization is becoming increasingly relevant for Bownty, which means that now is the perfect time for Pia Vemmelund to

  • 2015-03-25

    The Managing Director of Momondo, Pia Vemmelund takes the helm at Bownty

    Every year Bownty sell deals worth hundreds of millions, while revenue has tripled the past year alone. Internalization is becoming increasingly relevant for Bownty, which means that now is the perfect time for Pia Vemmelund to

  • 2015-03-23

    SEED Capital reports outstanding result for 2014

    The recently published accounts from SEED Capital reports four exits in the past year. We exited Contera Pharma, Libratone, Sense and Endomondo.

  • 2015-03-18

    Ambitious health app secures $900,000 investment

    Serbian TeleSkin won Europe's largest startup competition, Next Step Challenge, last year and the 1st prize of $300,000. Now they are accelerating their growth with a venture investment of $900,000.

  • 2015-03-18

    Reapplix Patents Granted in USA and Japan

    Reapplix, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.

  • 2015-03-12

    Inventor of superlight concrete wins prestigious prize

    The inventor of the so-called 'super light' concrete deck, DTU Professor Kristian Hertz, has been recognized with the award “betonprisen 2015”

  • 2015-03-12

    Venture investment brings wonder boys to market

    In 2014 AIRTAME raised a staggering $1.3m on Indiegogo, was awarded best startup at the world’s largest consumer electronics show, CES and received a Red Dot Award. Now they are accelerating their growth with a venture-investment.

Social

Twitter

Newsletter

Where to meet us

Press Kit

SEED Capital Ulla Brockenhuus-Schack

SEED Capital logo
Download as png (8 kb)
Download as eps (374 kb)

Ulla Brockenhuus-Schack
Download as jpg (1.1 mb)

Download our full press kit here

Contact Information
Communications Manager: Line Byrfelt Grønlykke
Phone: +45 4111 2191
E-mail: lbg@seedcapital.dk